Real Endpoints aims to simplify drug contracting process


Launches platform to expand access via value-based contracting arrangements

Real Endpoints (RE), an advisory and analytics firm focused on market access within the pharma industry, has launched RE Marketplace, a platform the company says will boost the efficiency and reach of value-based contracting for drugs for rare and orphan disease, providing significant benefits for patients, payers and manufacturers.

The founding members consist of four regional health plans, representing nearly 2.5 million beneficiaries. More plans are expected to join in the coming months.

Through value-based contracts, the platform accelerates the availability of rare-disease drugs to millions of members in mid-sized and smaller health plans who otherwise may not normally have access to these products.

Further, RE Marketplace provides each plan access to value-based agreements through a single contract for all participating biotech drugs, while biopharma manufacturers have contracted access to previously hard-to-reach plan members.

Using the medical and pharmacy claims data from the RE Marketplace member health plans, Real Endpoints and its academic partner, the University of Colorado Anschutz Medical Campus, will be responsible for performing all of the analytics and financial reconciliation, using a secure, HIPAA-compliant system that has already been tried and used in various deals.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.